What is the global market size of the Transcatheter Embolization and Occlusion Devices Market?

Global Transcatheter Embolization and Occlusion Devices Market size was valued at USD 5.76 billion in 2021 and is poised to grow from USD 5.1 billion in 2022 to USD 13.47 billion by 2030, growing at a CAGR of 9.89% in the forecast period (2023-2030).

Who are the key vendors in the Global Transcatheter Embolization and Occlusion Devices Market?

The global transcatheter embolization and occlusion devices market is highly competitive and characterised by the presence of several major players. These companies are engaged in continuous research and development activities to introduce innovative products and gain a competitive edge in the market. The competitive landscape is shaped by factors such as product offerings, technological advancements, strategic collaborations, and geographical presence. 'Medtronic (Ireland)', 'Boston Scientific Corporation (United States)', 'Stryker Corporation (United States)', 'Terumo Corporation (Japan)', 'Johnson & Johnson (United States)', 'Cook Medical (United States)', 'Abbott Laboratories (United States)', 'Merit Medical Systems, Inc. (United States)', 'Penumbra, Inc. (United States)', 'BTG International Ltd. (United Kingdom)', 'Cardiva Medical, Inc. (United States)', 'Cook Group Incorporated (United States)', 'Balt International (France)', 'Edwards Lifesciences Corporation (United States)', 'Penumbra, Inc. (United States)', 'Sirtex Medical Limited (Australia)', 'Teleflex Incorporated (United States)', 'Acandis GmbH (Germany)', 'AngioDynamics, Inc. (United States)', 'Gore Medical (United States)'

What is the key driver of the Global Transcatheter Embolization and Occlusion Devices Market?

The global market for transcatheter embolization and occlusion devices is witnessing growth due to the rising demand for minimally invasive treatment options. Patients and medical professionals are increasingly opting for these procedures because they offer benefits such as faster recovery times, shorter hospital stays, and reduced risk of complications. The preference for minimally invasive procedures is a major driver behind the increasing demand for transcatheter embolization and occlusion devices.

What is the key market trend for the Global Transcatheter Embolization and Occlusion Devices Market?

Adoption of New Technologies: New technologies are being developed that offer improved safety and efficacy, and these new technologies are expected to drive market growth in the coming years.In addition to the increasing adoption of new technologies, other key market trends for transcatheter embolization and occlusion devices include the increasing prevalence of chronic diseases, the rising demand for minimally invasive procedures, and the increasing adoption of reimbursement policies for these devices. As the market continues to grow, we can expect to see more innovation in the transcatheter embolization and occlusion devices industry, and this innovation is expected to help these devices become even more effective in treating a variety of medical conditions.

Which region accounted for the largest share in the Global Transcatheter Embolization and Occlusion Devices Market?

North America has emerged as the most dominant market for transcatheter embolization and occlusion devices. This can be attributed to the well-established healthcare infrastructure, high adoption rate of advanced medical technologies, and favourable reimbursement policies in countries like the United States and Canada. The presence of key market players and ongoing research and development activities in the region further contribute to its dominance.

Transcatheter Embolization and Occlusion Devices Market Size

Transcatheter Embolization and Occlusion Devices Market Insights

Transcatheter Embolization and Occlusion Devices Market size was valued at USD 4.82 Billion in 2023 and is poised to grow from USD 5.17 Billion in 2024 to USD 9.02 Billion by 2032, growing at a CAGR of 7.20% during the forecast period (2025-2032).

Healthcare spending worldwide supports the development of highly advanced medical technologies, including implantable catheter devices and occlusion devices. The aging population with its higher susceptibility to certain conditions further drives market growth. Good reimbursement policies and insurance coverage encourage health care providers to use and service these devices. While these factors contribute to market growth, it is important to consider factors such as regulations and competition that influence the transcatheter embolization and occlusion devices industry.

The transcatheter embolization and occlusion devices market is emerging with opportunities for growth and development. Enhancing the indications for these devices offers significant opportunities to treat a wide range of conditions. Growing markets in regions such as Asia-Pacific and Africa give manufacturers untapped potential to establish their presence. Technological advances such as advanced device design, advanced imaging guidance, and integrated medical activity provide innovative approaches. Collaboration and partnerships among health professionals, manufacturers, and research institutes stimulates research and development efforts, and expands the market. Educating patients and healthcare professionals about the benefits of minimally invasive treatments to drive demand. By capitalizing on these opportunities through innovation that combines artificial intelligence and data analytics with machine capabilities for precision planning, real-time guidance, and personalized medicine management.

FAQs

The competitive landscape of the transcatheter embolization and occlusion devices industry is characterized by numerous global and regional players investing in new products, strategies and geographical expansion to force them to build their market position strength. Key players focus on developing advanced embolic drugs, improving application, expanding their product lines to address various medical conditions. For example, partnerships between device manufacturing and clinical or research between institutions to stimulate clinical certification, product development and approval processes are common. 'Boston Scientific Corporation (US) ', 'Terumo Corporation (Japan) ', 'Medtronic (Ireland) ', 'Abbott (US) ', 'Cook Medical Inc. (US) ', 'Penumbra, Inc. (US) ', 'Cerenovus (a subsidiary of Johnson & Johnson) (US) ', 'Guerbet S.A. (France) ', 'Merit Medical Systems, Inc. (US) ', 'AngioDynamics, Inc. (US) ', 'B. Braun Melsungen AG (Germany) ', 'Humares (Germany) ', 'Inari Medical, Inc. (US) ', 'MicroVention, Inc. (US) ', 'Endospan Ltd. (Israel) ', 'Teleflex Incorporated (US) ', 'Kaneka Corporation (Japan) ', 'Abbott Vascular (a division of Abbott Laboratories) (US) ', 'SentreHEART, Inc. (US) ', 'Vascular Technologies (US)'

The increasing burden of chronic diseases such as cancer, liver disease and cardiovascular diseases is driving demand for less invasive medical solutions such as transcatheter embolization occlusion (TEO) devices. It is one of the leading causes of cancer death worldwide, especially for refractory tumors. Embolization techniques are emerging as an effective palliative treatment. This has led to the adoption of TEO devices by healthcare facilities to improve patient outcomes, contributing significantly to the transcatheter embolization and occlusion devices market growth.

Increasing Preference for Nonsurgical Treatment: Patients and health care providers are increasingly preferring minimally invasive surgery over conventional surgery due to decreased complications, shorter recovery times, and lower risks. Changing preferences has led to a demand for implantable devices as an alternative to open surgery. The trend is consistent with the global focus on patient-centered care, further increasing the use of TEO devices.

As per transcatheter embolization and occlusion devices market outlook, North America led the market with 29.7% revenue share in 2022. Availability of advanced healthcare infrastructure, well-defined regulatory framework, and skilled healthcare professionals are the major drivers for TEO demand devices in this region. According to the Centers for Disease Control and Prevention (CDC), these devices are used in cases of migraine and muscle spasms; Each year, 454,000 people are diagnosed with atrial fibrillation. The market is characterized by a few major players, including Abbott Laboratories, Boston Scientific Corporation, and Medtronic PLC, who are continuously innovating and expanding their product offerings to meet the growing demand.

Transcatheter Embolization and Occlusion Devices Market

Report ID: SQMIG35A2295

Transcatheter Embolization and Occlusion Devices Market Size

Transcatheter Embolization and Occlusion Devices Market Insights

Transcatheter Embolization and Occlusion Devices Market Report Snapshots

FAQs

Request Free Customization

Transcatheter Embolization and Occlusion Devices Market Size

Transcatheter Embolization and Occlusion Devices Market Insights

Transcatheter Embolization and Occlusion Devices Market Report Snapshots

FAQs

What is the global market size of Transcatheter Embolization and Occlusion Devices Market?

Who are the key vendors in the Transcatheter Embolization and Occlusion Devices Market?

What is the key driver of Transcatheter Embolization and Occlusion Devices Market?

What is the key market trend for Transcatheter Embolization and Occlusion Devices Market?

Which region accounted for the largest share in Transcatheter Embolization and Occlusion Devices Market?

Request Free Customization